Literature DB >> 15081257

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.

Karin Geleijns1, Bart C Jacobs, Wouter Van Rijs, Anne P Tio-Gillen, Jon D Laman, Pieter A van Doorn.   

Abstract

Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy preceded by infections. Campylobacter jejuni is the most frequent pathogen and its lipopolysaccharide (LPS) induces antibodies cross-reactive with gangliosides. In this study we assessed whether known functional polymorphisms in the LPS receptors CD14 and Toll-like receptor 4 (TLR4) are associated with an increased susceptibility for GBS or with C. jejuni serology or C. jejuni related clinical and serological features. Comparison of the genotypes of 242 GBS patients and 210 healthy subjects showed that polymorphisms in CD14 and TLR4 did not confer disease susceptibility and were not associated with C. jejuni infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081257     DOI: 10.1016/j.jneuroim.2004.01.003

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  The role of Toll-like receptor 4 polymorphisms in vaccine immune response.

Authors:  P Pellegrino; F S Falvella; S Cheli; C Perrotta; E Clementi; S Radice
Journal:  Pharmacogenomics J       Date:  2015-03-31       Impact factor: 3.550

Review 2.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

3.  Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.

Authors:  S Usuki; K Taguchi; S A Thompson; P B Chapman; R K Yu
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 4.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

5.  Genome-Wide Association Study of Campylobacter-Positive Diarrhea Identifies Genes Involved in Toxin Processing and Inflammatory Response.

Authors:  Rebecca M Munday; Rashidul Haque; Ning-Jiun Jan; Genevieve L Wojcik; Chelsea Marie; Dylan Duchen; Alexander J Mentzer; Uma Nayak; Poonum Korpe; Beth D Kirkpatrick; William A Petri; Priya Duggal
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

Review 6.  Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.

Authors:  Kishan Kumar Nyati; Kashi Nath Prasad
Journal:  Mediators Inflamm       Date:  2014-09-22       Impact factor: 4.711

7.  Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS.

Authors:  Willem-Jan R Fokkink; Annechien E G Haarman; Anne P Tio-Gillen; Wouter van Rijs; Ruth Huizinga; Pieter A van Doorn; Bart C Jacobs
Journal:  Ann Clin Transl Neurol       Date:  2016-05-17       Impact factor: 4.511

8.  Toll-like receptor-4 299Gly allele is associated with Guillain-Barré syndrome in Bangladesh.

Authors:  Israt Jahan; Rijwan U Ahammad; Mir M Khalid; Mohammad I Rahman; Shoma Hayat; Badrul Islam; Quazi D Mohammad; Zhahirul Islam
Journal:  Ann Clin Transl Neurol       Date:  2019-03-03       Impact factor: 4.511

9.  Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis.

Authors:  Yoon Young Cho; Ji Young Joung; Hyemin Jeong; Dongmo Je; Yun Soo Hong; Sunghwan Suh; Sun Wook Kim
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

10.  Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk.

Authors:  Mehdi Moghadampour; Ebrahim Eskandari-Nasab; Fatemeh Shabani
Journal:  Asian Pac J Trop Med       Date:  2016-01-12       Impact factor: 1.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.